Eli Lilly and Company

Vertex Pharmaceuticals, Inc.

Mark Joseph Tebbe

Frantz Victor

Wayne A Spitzer

Shawn Christopher Miller

Xicheng David Sun

Louis Nickolaus Jungheim

Deqi Guo

Nancy June Snyder

John Irvin Glass

Q May Wang

Jason Eric Lamar

Cristina Garcia-Paredes

Robert Edward Babine

Yvonne Yee Mai Yip

Ivan Collado

Ling Jin

Raymond Samuel Parker, Iii

Luc J Farmer

Robert B Perni

Joseph Chiou-Chung Tang

Joseph Matthew Colacino

Shu Hui Chen

Thomas R Sattelberg, Sr

Beverly Ann Heinz

Pamela Ann Albaugh

Andreas Gerhard Weichert

Timothy Paul Burkholder

James Robert Henry

Guoxin Zhu

Sushant Malhotra

Scott Eugene Conner

Joshua Ryan Clayton

John Arnold Werner

Thomas Albert Engler

Yihong Li

Kelly Wayne Furness

Eva Maria Martin De La Nava

Britta Evers

David Gene Barrett

Brian Eugene Cunningham

John Morris Sullivan

Steven Eugene Dunlap

Jochen Ammenn

Shu-Hui Chen

Stefan Heuser

Brian Raymond Berridge

Charles Edward Ruegg

Rainer Riedl

Gilbert Thomas Voy

Ruehter Gerd

Andrea Zaliani

May Q Wang

Mai Yee Yvonne Yip

Samuel Raymond Parker Iii

Samuel Raymond Iii Parker

Raymond Samuel Iii Parker

Deqi Duo

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Peptidomimetic protease inhibitors

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof. 

Substituted arylcyclopropylacetamides as glucokinase activators

The present invention provides kinase inhibitors of Formula (I) 

Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

Growth hormone secretagogues

The present application provides a series of benzimidazole compounds of formula I: ##STR1## which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.

Anti-viral compounds

A series of benzimidazole compounds having the following general structure are provided which inhibit the growth of picornaviruses (e.g., rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus) and flaviviruses (e.g., hepatitis C and bovine diarrheal virus). ##STR1## A method for inhibiting picornaviruses and flaviviruses is also provided which includes administering to a host an effective amount of the inventive benzimidazole compounds.

Anti-viral compound

The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus and flaviviruses such as hepatitis C and bovine diarrheal virus.

Certain vinyl acetylene benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus.

The present application provides a series of benzimidazole compounds which inhibit the growth of picornaviruses, such as rhinoviruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.

Growing community of inventors

Hamburg, Germany

Mark Joseph Tebbe